Stay updated on PAlbociclib & ctDNA for ESR1 Mutations Clinical Trial

Sign up to get notified when there's something new on the PAlbociclib & ctDNA for ESR1 Mutations Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PAlbociclib & ctDNA for ESR1 Mutations Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the study related to the efficacy of a change in hormone therapy combined with palbociclib for ER-positive HER2-negative metastatic breast cancer patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:51:15.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' which now includes examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' has been expanded to provide detailed inclusion and exclusion criteria for the study.
    Difference
    40%
    Check dated 2024-05-22T21:20:38.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:36:07.000Z thumbnail image

Stay in the know with updates to PAlbociclib & ctDNA for ESR1 Mutations Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PAlbociclib & ctDNA for ESR1 Mutations Clinical Trial page.